Osmol Therapeutics

According to this article in Inside Precision Medicine, patients who experience painful CIPN symptoms often face significant limitations in their daily lives, a worse quality of life, and financial struggles. In addition, treatment outcomes and survival rates can be impacted when chemotherapy is reduced or discontinued entirely as a result of severe cases.   At Osmol, we believe patients shouldn’t have to choose between effective cancer treatment and their long-term quality of life. That’s why we’re working to prevent CIPN before it starts, allowing patients to focus on recovery—not lasting side effects.   Read the full article here: https://bit.ly/3Dt1YpB

DYKT Black breast cancer survivors may be disproportionately affected by chemotherapy-induced peripheral neuropathy (CIPN)? Learn about the research via Oncology Nursing News, which sheds light on how racial disparities in cancer care can leave lasting impacts on survivors. At Osmol, our work focuses on prevention, aiming to stop CIPN before it starts so patients can focus on recovery, not side effects. Read the full article: https://bit.ly/4htGtDO

Cancer treatment saves lives, but for many survivors, the journey doesn’t end when treatment stops. According to American Association for Cancer Research, 18 million cancer survivors in the U.S. are living with, through, and beyond their disease. For many, chemotherapy-induced peripheral neuropathy (CIPN) remains a debilitating, life-long side effect—impacting mobility, daily activities, and overall well-being. At Osmol, we are committed to preventing the overlooked challenges of cancer treatment. Our groundbreaking approach targets CIPN and chemotherapy-induced cognitive impairment (CICI), commonly associated with taxane-based chemotherapies, so patients don’t have to choose between treatment success and quality of life. This National Cancer Prevention Month, we also recognize the strength of survivors. By addressing the lasting effects of chemotherapy, we can improve outcomes and ensure that more patients thrive beyond their diagnosis. Learn how OSM-0205 is striving to address this critical challenge in cancer care: https://bit.ly/3WVNXaj

ICYMI: #BiotechShowcase 2025 presentation – webcast now available! Listen in as our CEO, Bob Linke, shares the groundbreaking potential of OSM-0205, a first-in-class treatment for chemotherapy-induced peripheral neuropathy (CIPN) and chemotherapy-induced cognitive impairment (CICI), in hopes of easing the journey for cancer patients. Webcast will be available for six months: https://bit.ly/4hj6ANb

✋ Who's headed to #NEXUS2025 in San Francisco for the week? 🗣️ Don't miss Bob Linke, CEO, as he discusses how OSM-0205's first-in-class mechanism is paving the way for improved patient outcomes by addressing chemotherapy-induced side effects like chemotherapy-induced peripheral neuropathy (CIPN) and chemotherapy-induced cognitive impairment (CICI). We're proud to contribute to these critical conversations to enhance patients' lives. Don't miss tomorrow's presentation during the Biopharma Track. https://bit.ly/426V6bi Blinkpad #JPMHealthcareWeek

We’re headed to #NEXUS2025 – a gathering of innovators, investors, and thought leaders shaping the future of healthcare. Our CEO, Bob Linke, will present during the Biopharma Track on Tuesday, January 14, in South San Fran. Bob will spotlight OSM-0205, our lead candidate, and its potential to transform cancer care by addressing chemotherapy-induced peripheral neuropathy (CIPN) and chemotherapy-induced cognitive impairment (CICI). Learn more and register here: https://bit.ly/426V6bi #JPMHealthcareWeek MT Blinkpad

We’re less than a week away from our presentation at #BiotechShowcase. Join us on Monday, January 13, 2025, at 10:30 AM PT to learn how OSM-0205, our lead candidate, is poised to address critical challenges in cancer treatment, including chemotherapy-induced peripheral neuropathy (CIPN) and chemotherapy-induced cognitive impairment (CICI). Additionally, you can schedule a 1:1 with our CEO, Bob Linke, as part of the partnering program. Reach out to schedule a meeting with a inbox message or visiting our website: https://lnkd.in/eT-Z6X2N #JPMHealthcareWeek

We’re less than a week away from our presentation at #BiotechShowcase. Join us on Monday, January 13, 2025, at 10:30 AM PT to learn how OSM-0205, our lead candidate, is poised to address critical challenges in cancer treatment including chemotherapy-induced peripheral neuropathy (CIPN) and chemotherapy-induced cognitive impairment (CICI). Additionally, you can schedule a 1:1 with our CEO, Bob Linke, as part of the partnering program. Reach out to schedule a meeting with an inbox message or by visiting our website: https://lnkd.in/eT-Z6X2N

A recent article in The Wall Street Journal highlighted that more and more people are surviving cancer, but that life after chemo is more challenging than anticipated. The side effects of chemo can often impact the quality of life for patients long after treatment ends. 👉There are over 18 million U.S. cancer survivors today 👉Many under 50 years of age with decades of life ahead of them 👉This number is expected to grow to 26 million by 2040 Our lead candidate, OSM-0205, aims to prevent chemotherapy-induced peripheral neuropathy (CIPN) and chemotherapy-induced cognitive impairment (CICI) before they impact patients – paving the way for optimal chemotherapy dosing and enhanced patient outcomes. Learn more: https://lnkd.in/euAQeFHF If you're a WSJ subscriber, access the article, "She Beat Cancer at 27. Her Struggle Was Just Beginning," here: https://on.wsj.com/4fl2RNF

Our CEO, Bob Linke, will be participating in the dynamic 1:1 partnering program at #BiotechShowcase in San Fransico. To learn more about how OSM-0205 is paving the way for better outcomes in cancer treatment by addressing chemotherapy-induced peripheral neuropathy (CIPN) and chemotherapy-induced cognitive impairment (CICI), schedule a meeting with Bob. Send your request via an inbox message or contact us via our website:  https://lnkd.in/eT-Z6X2N